Inherited Prion Disease A117V Is Not Simply a Proteinopathy but Produces Prions Transmissible to Transgenic Mice Expressing Homologous Prion Protein. by Asante, EA et al.
Inherited Prion Disease A117V Is Not Simply a
Proteinopathy but Produces Prions Transmissible to
Transgenic Mice Expressing Homologous Prion Protein
Emmanuel A. Asante, Jacqueline M. Linehan, Michelle Smidak, Andrew Tomlinson, Andrew Grimshaw,
Asif Jeelani, Tatiana Jakubcova, Shyma Hamdan, Caroline Powell, Sebastian Brandner,
Jonathan D. F. Wadsworth, John Collinge*
Medical Research Council Prion Unit and Department of Neurodegenerative Disease, University College London Institute of Neurology, Queen Square, London, United
Kingdom
Abstract
Prions are infectious agents causing fatal neurodegenerative diseases of humans and animals. In humans, these have sporadic,
acquired and inherited aetiologies. The inherited prion diseases are caused by one of over 30 coding mutations in the human
prion protein (PrP) gene (PRNP) and many of these generate infectious prions as evidenced by their experimental
transmissibility by inoculation to laboratory animals. However, some, and in particular an extensively studied type of
Gerstmann-Stra¨ussler-Scheinker syndrome (GSS) caused by a PRNP A117V mutation, are thought not to generate infectious
prions and instead constitute prion proteinopathies with a quite distinct pathogenetic mechanism. Multiple attempts to
transmit A117V GSS have been unsuccessful and typical protease-resistant PrP (PrPSc), pathognomonic of prion disease, is not
detected in brain. Pathogenesis is instead attributed to production of an aberrant topological form of PrP, C-terminal
transmembrane PrP (CtmPrP). Barriers to transmission of prion strains from one species to another appear to relate to structural
compatibility of PrP in host and inoculum and we have therefore produced transgenic mice expressing human 117V PrP. We
found that brain tissue from GSS A117V patients did transmit disease to thesemice and both the neuropathological features of
prion disease and presence of PrPSc was demonstrated in the brains of recipient transgenic mice. This PrPSc rapidly degraded
during laboratory analysis, suggesting that the difficulty in its detection in patients with GSS A117V could relate to post-
mortem proteolysis. We conclude that GSS A117V is indeed a prion disease although the relative contributions of CtmPrP and
prion propagation in neurodegeneration and their pathogenetic interaction remains to be established.
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Introduction
According to the widely accepted ‘‘protein-only’’ hypothesis [1],
an abnormal isoform (PrPSc) of host-encoded cellular prion protein
(PrPC) is the principal, and possibly the sole, constituent of the
transmissible agent or prion [2]. Prions exist in multiple strains
which are thought to represent distinct polymeric forms of
misfolded PrP which faithfully propagate by recruitment of host
PrPC onto pre-existing seeds or fibrils (for review see [3]). Human
prion diseases may occur sporadically, be acquired by infection
with environmental prions, or be inherited as autosomal dominant
conditions as a result of one of more than 30 different coding
mutations in the human PrP gene (PRNP) [4]. The cause of
neuronal dysfunction and death in prion disease is unclear but
neurotoxicity may be uncoupled from infectivity suggesting that
prions themselves may not be directly neurotoxic and other PrP
species might be involved in mediating toxicity [3,5,6].
By definition, prion diseases are transmissible, and while all
the sporadic and acquired human prion diseases have been
transmitted to laboratory animals, not all of the inherited forms
have. It has been suggested therefore that some of these inherited
neurodegenerative syndromes are prion proteinopathies with a
distinct pathogenesis that may not involve production of infectious
prions. One inherited prion disease (IPD) in particular, associated
with an alanine to valine substitution at residue 117 of PrP
(A117V), has been proposed to cause neurodegeneration in the
absence of PrPSc, with pathogenesis mediated by aberrant
production of CtmPrP, a transmembrane form of PrP [7]. It has
also been proposed that PrPSc accumulation in other forms of
prion disease may cause pathology by inducing the synthesis of
CtmPrP de novo [8]. This aberrant topologic form of PrP has been
hypothesised to cause neurologic dysfunction by disrupting the
function of mahogunin, a cytosolic ubiquitin ligase whose loss
causes spongiform neurodegeneration [9]. However, a recent
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study using mice lacking the Mahogunin Ring Finger 1 (MGRN1)
E3 ubiquitin ligase concluded that disruption of MGRN1-
dependent pathways does not play a significant role in the
pathogenesis of prion diseases [10].
A117V is one of the IPD mutations associated phenotypically
with the Gerstmann-Stra¨ussler-Scheinker syndrome (GSS) which
usually presents clinically as a progressive cerebellar ataxia with
dementia occurring later in a clinical course usually far more
protracted than that of Creutzfeldt-Jakob disease (CJD) [11].
Pathologically, GSS is characterised by the presence of multicen-
tric PrP amyloid plaques. However, in common with other IPD’s,
A117V has a wide phenotypic diversity at both the clinical and
pathological level even within the same kindred [11]. This disease
was originally misdiagnosed as Alzheimer’s disease [12] before the
advent of PrP immunohistochemistry [13] and the subsequent
identification of the A117V mutation by PRNP sequencing [14].
A major determinant of phenotypic heterogeneity in prion
diseases of humans and animals is prion strain diversity, with
distinct prion strains producing characteristic clinical and patho-
logical phenotypes [15]. Prion strains can be distinguished by
biochemical differences in PrPSc, referred to as molecular strain
typing [16]. In a number of inherited prion diseases, distinct PrPSc
types have been reported associated with the same PRNP
pathogenic mutation and this may in part explain phenotypic
heterogeneity (for review see [17,18]). In this regard while classical
CJD is typically characterised by proteinase K-resistant PrP
fragments of ,21–30 kDa on immunoblots [19] most GSS cases
show additional low molecular mass fragments of 7–15 kDa [19–
27]. Notably, the major protease-resistant peptide extracted from
brains of GSS A117V patients is a ,7–8 kDa PrP fragment [26],
and to-date it has not been possible to detect proteolytic fragments
of molecular mass 21–30 kDa in these samples. The pathogenic
role of the PrP species from which the 8 kDa fragment is
generated is not clear because, inocula containing this fragment
induced conversion of murine 101L-PrP into amyloid but did not
induce spongiform neurodegeneration in the recipient mouse
brains [28]. These facts coupled with the negative experimental
transmission data have led to the suggestion that GSS A117V may
not be an authentic prion disease and would be more accurately
described as a non-transmissible proteinopathy [29,30].
That most sporadic and acquired CJD occurred in individuals
homozygous at PRNP polymorphic codon 129 supported the view
that prion propagation proceeded most efficiently when the
interacting PrPSc and PrPC were of identical primary structure
[31,32]. It has been demonstrated that the species barrier may be
abrogated in transgenic mice expressing PrP homologous to that of
the exogenous PrPSc [33]. This is also the case with transmission of
human prion diseases. Classical CJD transmits rarely if at all to
wild type mice but highly efficiently (indeed without a transmission
barrier) to mice expressing human (and not mouse) PrP [34,35].
However, prion strain type may also play a key role in
transmission barriers, which are thought to be mediated via
conformational selection where a given PrP primary structure has
a preferred subset of disease-associated conformations it can adopt
[3,36]. While therefore it is possible that some naturally occurring
human prion strains could transmit more efficiently for example to
wild type mice rather than to mice transgenic for a particular
human PrP polymorph (as is the case for vCJD for example [37]),
it is logical to test for transmissibility of GSS A117V using
transgenic mice expressing only human PrP 117V.
Here we present the first evidence that IPD A117V cases
produce transmissible prions; previous transmission attempts may
have failed from use of inappropriate experimental models.
Furthermore, we show that the previous failure to detect PrPSc
in GSS A117V patient brain may have been due to its unusual
instability with consequent loss by post-mortem proteolysis in
human brain samples.
Results
Susceptibility of transgenic mice expressing only human
PrP 117V to sporadic and acquired CJD prions
We produced transgenic mice homozygous for both a human
PrP 117V, 129V transgene array and murine PrP null [38] alleles
(Prnpo/o), designated Tg(HuPrP117V,129V+/+ Prnpo/o)-31 (hereafter
referred to as 117VV Tg31), with human PrP expression levels
three times that of pooled normal human brain (data not shown).
We studied an ageing cohort of 20 mice for evidence of
spontaneous neurodegeneration, however all of these uninoculated
mice died of intercurrent illnesses or old age between 460 and 904
days without developing neurological disease. In addition, three
out of a further control group of five mice mock-inoculated with
PBS buffer lived to between 344 and 735 days post-inoculation
without developing neurological signs. One mouse was scored
clinically sick at 303 days post inoculation (Table 1) but this and
two other PBS-inoculated mice had no evidence for pathological
PrP in brain by either immunoblotting or immunohistochemistry
(IHC). One mouse, culled at 582 days post-inoculation due to
intercurrent illness, although negative for PrPSc by immunoblot-
ting was found to have minor PrP immunoreactivity in the
anterior commissure by IHC (Figure S1A). This finding in a single
sample was not studied further.
To assess the susceptibility of these novel transgenic lines to
prion infection, we first inoculated them with well characterised
isolates of classical CJD with proven transmissibility to mice
expressing wild-type human PrP [35,37,39,40] although recognis-
ing that the presence of the A117V mutation may introduce a
transmission barrier to prions generated from wild-type PrP.
Sporadic CJD isolate I022 (PRNP 129VV with type 2 PrPSc)
caused clinical disease in 2/6 mice with relatively short incubation
periods of 263 and 303 days post-inoculation (Table 1). Although
clinical attack rate was low, most mice (5/6) were subclinically
Author Summary
Prions are infectious agents causing incurable brain
disease in humans and animals. Prion diseases are by
definition transmissible, which means that it should be
possible to experimentally transfer disease from patient
brain tissue to laboratory animals by inoculation. While
many forms of prion disease have been shown to be
experimentally transmissible, some inherited forms, in
particular, Gerstmann-Stra¨ussler-Scheinker syndrome
(GSS) associated with the substitution of valine for alanine
at amino acid position 117 (GSS A117V) of the human
prion protein gene have not. This has led to the
suggestion that such syndromes are not true prion
diseases and are better designated non-transmissible
proteinopathies. Since prions may transmit more efficiently
when the host’s normal prion protein amino acid sequence
matches that of the infecting prion, we generated
transgenic mice expressing human prion protein with
the same amino acid sequence found in A117V GSS. We
found that brain tissue from GSS A117V patients could
transmit disease to these mice, producing the typical brain
lesions associated with GSS A117V. We therefore conclude
that GSS A117V is an authentic prion disease.
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infected and showed positivity for abnormal PrP by IHC and/or
immunoblotting (Table 1). In contrast, other inocula comprising
sporadic CJD and iatrogenic CJD with different PRNP codon 129
status and PrPSc types, and also vCJD and vCJD passaged in
129VV Tg152 mice (which contained type 5 PrPSc [37,40])
transmitted very poorly or not at all (Table 1). Collectively these
findings show that at 3-fold expression level of human PrP, 117VV
Tg31 mice can replicate human prions, although this varies with
prion strain and codon 129 genotype effects.
Susceptibility of transgenic mice expressing only human
PrP 117V to IPD A117V inocula
117VV Tg31 mice were inoculated with three isolates of GSS
A117V and remarkably all resulted in transmission with clinically
affected mice (Table 1). To our knowledge this is the first time
these isolates have been shown to have transmissible prions.
However, it should be noted that clinical transmissions were
associated with extremely long incubation periods, ranging from
609 to 673 days post-inoculation (Table 1). It is therefore
unsurprising that previous attempts to transmit this disease, into
animals expressing endogenous levels of a PrP of different primary
structure, were completely unsuccessful [41,42].
Sub-clinical prion infection in mice expressing human PrP
A117V
We investigated all the clinically unaffected mice challenged
with brain homogenates from GSS A117V patients or classical
CJD prions for evidence of subclinical infection [5,39,43] by both
PrP immunohistochemistry and immunoblotting. We found that
6/8 of the mice inoculated with GSS A117V prion isolate I514
were positive by immunohistochemistry (Figure 1 A–D), although
only 2/9 showed clinical signs (Table 1). In contrast to sporadic
CJD inoculum I022 which produced only synaptic type PrP
deposits (Figure 1E and G), all three IPD A117V inocula resulted
in intense deposition of PrP plaques in cerebral cortex,
hippocampus, thalamus and cerebellum (Figure 1A and C). There
was neuronal loss (Figure S1B and Figure 2) and spongiosis, more
pronounced in the white matter (Figure 1B), and gliosis (Figure 1D
and Figure 2) that reflected the extent of the PrP plaque load. Sub-
clinical infection was also prominent in 117VV Tg31 mice
challenged with sporadic CJD inoculum I022, with 5/6 mice being
positive by immunohistochemical analysis (Table 1, Figure 1 E–H)
despite a low clinical attack rate of 2/6.
PrPSc can be propagated in mice expressing only human
PrP 117V
The classical proteolytic PrPSc fragments of ,21–30 kDa have
to-date not been detected in brain from A117V patients. We
Figure 1. Neuropathological analysis of transgenic mouse brain. Panels A, E, I and M, schematics showing regional distribution of abnormal
PrP deposits. Note that these panels reflect the overall spatial distribution of neuropathology and are not meant to indicate precise representations of
individual brains. Panels B, F, J and N, H&E staining demonstrating spongiform neurodegeneration in the hippocampal areas. Panels C, G, K and O, PrP
immunohistochemistry using anti-PrP monoclonal antibody ICSM 35 demonstrates abnormal PrP immunoreactivity. Panels D, H, L and P, GFAP
staining demonstrating gliosis in the hippocampal areas. A–D, IPD A117V prions inoculated to 117VV Tg31 mouse; E–H, sporadic CJD prions
inoculated to 117VV Tg31 mouse showing distinctive diffuse synaptic PrP deposition characteristic of sCJD prions (panel G); I–L, IPD A117V prions
inoculated to 117VV Tg30 mouse. M–P, vCJD prions inoculated to 117VV Tg30 mouse showing abundant non-florid PrP plaques (panel O). Scale
bar = 500 mm for all panels except A, E, I and M.
doi:10.1371/journal.ppat.1003643.g001
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analysed the brains of all clinically affected mice and those that
died of inter-current illnesses by immunoblotting for the presence
of PrPSc. We first confirmed that 117VV Tg31 mice are capable of
producing stable PrPSc by analysing brains of mice inoculated with
sporadic CJD prions. In order to adequately digest PrPC in these
mice, we used stringent PK digestion conditions of 100 mg/ml
incubated at 37uC for 1 hour, and demonstrated the presence of
PrPSc in the brains of A117V Tg31 mice inoculated with sporadic
CJD inoculum.
Immunoblots show clear evidence that 117V PrPC is convertible
to PrPSc in 117VV Tg31 mice challenged with sporadic CJD
inoculum I022 (Figure 3A, lanes 3, 4 and 7) and is present at
similar levels in control mice expressing wild type human PrP-
129MV challenged with the same prion inoculum (Figure 3A, lane
1). Transmission of iatrogenic CJD prion isolate I1477 to 117VV
Tg31 mice shows a low intensity positive signal associated with the
brain of a subclinically infected mouse culled 804 days post-
inoculation (Figure 3B lane 4), which when compared with the
absence of signal in a second mouse culled relatively early at 294
days post-infection (lane 3) probably reflects the relative abun-
dance of 117V PrPSc accumulated over the respective survival
periods.
Having established that 117V PrPC would support the
propagation of conventional PrPSc in our transgenic mice, we
analysed brains of 117VV Tg31 mice that were inoculated with
GSS A117V prions for the presence of disease-related PrP.
Encouraged by the confirmation that these 117VV mice can
replicate human prions, and to adequately digest PrPC in these
mice which express at higher levels, we used relatively harsh PK
conditions (100 mg/ml PK at 37uC for 1 hour) and found that five
brain samples analysed showed variable PK resistance (Figure 3C,
lanes 3–7). Brain samples appear to have achieved only partial
digestion even under these conditions, and displayed concurrently
the presence of PrPC, PrPSc 21–30 kDa fragments and extra
fragments of about 7–8 kDa (Figure 3C lanes 4–6). The presence
of multiple PK digestion products seen on immunoblots was not
due to inadequate PK digestion parameters because under the
same conditions an inoculated 117VV Tg31 mouse that was killed
due to intercurrent illness at 188 days post-inoculation (Figure 3C,
lane 3), and a PBS-inoculated control mouse killed due to
intercurrent illness at 569 days post-inoculation (Figure 3C, lane 8)
showed only residual PrPC signal that was only visible after long
exposure.
Notably, one brain sample (Figure 3C, lane 7) achieved
complete digestion with 100 mg/ml PK at 37uC for 1 hour, and
clearly shows the presence of PrPSc at a level comparable to the
positive control sample in lane 1. Interestingly, the 8 kDa PrP
fragment was not detected in this sample.
117V- human PrPSc is more labile than classical CJD PrPSc
As this was the first demonstration of detectable classical PrPSc
(generating PK-resistant fragments equivalent to PrP27–30 [44])
associated with GSS A117V, we sought to reproduce the
immunoblotting results but we were surprised to find that after
freeze-thawing of the brain homogenates, we were unable to
demonstrate PrPSc under the same harsh proteinase K (PK)
conditions of 100 mg/ml at 37uC for 1 hour (Figure S2 A and B).
Figure 3D shows the same sample in Figure 3C lane 7 that on
repeat western blotting and exposure for the same length of time
showed only a weak PrP27–30 signal at much reduced PK
concentration of 10 mg/ml digested at 37uC for 1 hour. Repeat
immunoblotting of the three other 117VV Tg31 brain homoge-
Figure 2. Overview of histological findings in 117VV HuPrP transgenic mice challenged with A117V prion isolates. The figures are
schematic drawings reflecting the overall spatial distribution and intensity pattern of the gliosis or PrP deposition within the experimental groups.
They are not meant to indicate precise representations of individual brains. * Definition of values for neuronal loss: NL0: No neuronal loss; NL+: Drop
out of single neurones either focally or within the Ammon’s horn (AH), leaving the AH continuity intact; NL++: Focal or regional drop out, interrupting
the continuity of the AH and creating a small-medium gap (up to 1/3 of the length of the AH); NL+++: Neuronal drop out leaving gaps of more than
1/3 of the AH’s length. Ratios represent the proportion of samples with the corresponding neuronal loss score.
doi:10.1371/journal.ppat.1003643.g002
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Figure 3. Immunoblot analysis of abnormal PrP propagated in the brains of 117VV transgenic mice challenged with IPD A117V and
classical CJD. Mice were inoculated with classical CJD and GSS A117V brain. Immunoblots were analysed by enhanced chemiluminescence with
monoclonal anti-PrP antibody ICSM 35. The numbers in parentheses above relevant lanes, represent the number of days each mouse survived post-
inoculation. The provenance of each brain sample is designated above each lane. (A) Immunoblots of sporadic CJD-inoculated 117VV Tg31 mice
(lanes 3–7) showing PrPSc resistant to harsh proteinase K (PK) digestion performed with 100 mg/ml PK at 37uC for 1 h (lanes 3, 4, and 7). Positive
control was from a transgenic mouse expressing wild type HuPrP-129MV challenged with the same CJD inoculum (lanes 1and 2). An uninoculated
117VV Tg31 mouse brain is shown in lanes 8 and 9. (B) Brain homogenate of a 117VV Tg31 mouse inoculated with iatrogenic CJD prions that died
without clinical disease at 804 days post-infection, showing weakly detectable PrPSc partially resistant to harsh PK digestion of 100 mg/ml for 1 hour
at 37uC (lane 4) compared to the same control as in Figure 3A (lanes 1 and 2). Brain homogenate of a mouse killed relatively early at 294 days post-
inoculation, shows no detectable PrPSc (lane 3). (C) Immunoblots of brains of five separate 117VV Tg31 mice all inoculated with the same GSS A117V
patient brain homogenate showing the presence of PrPC, PrPSc and 8 kDa PrP fragment following harsh PK digestion at 100 mg/ml PK at 37uC for
1 hour (lanes 3–7). Under these conditions PBS-inoculated age-matched control 117VV Tg31 mouse brain shows only residual PrPC signal on long
exposure (lane 8). Brain homogenate of a mouse culled relatively early at 188 days post-inoculation, compared to the group mean survival post-
Transmissibility of GSS A117V
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nates shown in Figure 3C lanes 4–6, even at drastically reduced
PK concentrations were negative for disease-associated PrP bands
and showed only residual non-digested bands corresponding to
PrPC (data not shown). Of note, immunoblotting of the same
samples in the absence of PK digestion showed that PrPC
remained relatively stable in these samples (data not shown).
These results strongly suggest that 117V PrPSc is significantly more
labile than that seen in CJD and other human prion diseases. The
remarkable difference in migration patterns between classical
CJD-challenged (Figure 3A lanes 3, 4, and7) and those of IPD
A117V-challenged Tg31 mice (Figure 3C lanes 4–5) is a further
reflection of the unique properties of A117V prions that set them
apart from those of classical CJD prions.
Transmission of human cases to a further HuPrP 117V-
expressing transgenic line
To corroborate these novel findings, we also inoculated a
second transgenic line expressing HuPrP 117V PrPC, called
Tg(HuPrP117V,129V+/+ Prnpo/o)-30 (designated 117VV Tg30), with
the same three IPD A117V prion isolates in addition to one case of
classical CJD and the same case of vCJD (Table 2). The 117VVTg30
mice were produced similarly to 117VV Tg31 mice but have a level
of human PrP expression two-fold higher than a pooled normal
human brain standard (data not shown), as compared with the 3-fold
PrP overexpression in the 117VV Tg31 line. Consistent with the low
rate of clinical disease in 117VV Tg31 mice, the 117VV Tg30 mice
did not show a single case of clinical disease from any of the inocula
administered (Table 2). However, as seen with prion-inoculated
117VV Tg31 mice, evidence of sub-clinical prion infection as
measured by positive immunohistochemistry was seen in the majority
of inoculated mice (Table 2 and Figure 1, I–L). Additionally,
immunohistochemical analysis of the brains of 117VV Tg30 mice
inoculated with GSS A117V prion isolate I514 all showed
pathological lesions characterised by gliosis (Figure 1L) and spongiosis
(Figure 1J) that reflected the level of PrP plaques (Figure 1K)
deposited in a similar pattern to 117VV Tg31 mice described
above. Spongiosis was more pronounced in white matter and
neuronal loss was prominent (Figure S1B and Figure 2). Two other
A117V prion inocula (I1321 and I1322) produced neuropatholog-
ically similar patterns to that of I514, though the plaque load was
slightly less (Figure 2). In all GSS A117V prion-infected 117VVTg30
mice only the 8 kDa PrP fragment was detected (Figure 3E lanes 7
and 8).
Interestingly, and in contrast to the Tg31 mice with higher
levels of expression of the mutant protein, we observed sponta-
neous clinical disease in three mice at between 476 and 742 days
in an ageing cohort of 20 uninoculated mice. This was associated
with PrP plaque deposition in the anterior commissure (data not
shown). We are currently investigating whether this pathology is
transmissible on sub-passage.
vCJD prions transmit to 117VV transgenic mice without
producing florid plaques
We also investigated the pattern of neuropathology produced in
vCJD-inoculated 117VV Tg30 mice. One of 3 positive samples
showed abundant plaques in the cerebral cortex, hippocampus,
thalamus and cerebellum (Figure 1M and O). Although neuronal
loss was present, there were no florid plaques, consistent with the
propagation of vCJD in the PRNP 129VV genotype [37,40].
However, while only a few non-florid plaques are typically seen
inoculation of .616 days, showed no detectable PrPSc (lane 3). One 117VV Tg31 mouse was clinically sick at 673 days post-infection, and its brain
sample shows complete digestion of PrPC and the presence of classical PrPSc (lane 7, denoted by *) confirming adequacy of the PK digestion
conditions. (D) Immunoblotting was repeated for all samples shown in lanes 4–7 of Figure 3C. These samples had undergone only one further freeze–
thaw cycle before PK digestion. Compared with the readily detectable abnormal PrP signals seen in Figure 3C, only one sample (denoted by *) now
showed the presence of classical PrPSc but at reduced signal strength, and only after using PK at a reduced concentration of 10 mg/ml. In other
samples, only an 8 kDa PrP fragment could be variably detected but after using reduced PK concentrations (see Figure S2B lanes 3 and 4). (E)
Immunoblot showing only the 8 kDa PrP fragment associated with A117V-challenged 117VV Tg30 mouse brains analysed with 50 mg/ml PK at 37uC
for 1 hour (lanes 7 and 8), whereas PrP in brain homogenates of PBS-challenged Tg30 mice (lanes 3–6) and uninoculated age-matched Tg30 mouse
brain (lane 9) is completely digested under the same conditions. Positive control in lanes 1 and 2 is brain homogenate of a transgenic mouse
expressing wild type HuPrP (129MM Tg35) that was challenged with classical CJD.
doi:10.1371/journal.ppat.1003643.g003
Table 2. Primary transmission of classical CJD, Inherited Prion Disease A117V and vCJD prions to transgenic mice expressing
huPrP117V,129V+/+ (117VV Tg30).
Inoculum
Aetiology Code
PRNP 129
genotype
Human PrPSc
type*
Clinical
Signs
Incubation
period (days
± sem)
Positive by
IHC Positive by IB
Total
affected{
8 kDa 21–30 kDa
PBS I056 - - 0/4 .490 0/4 0/4 0/4 0/4
IPD A117V I514 VV N/D 0/5 .400 4/4 5/5 0/5 5/5
I1321 VV N/D 0/5 .461 4/5 5/5 0/5 5/5
I1322 VV N/D 0/4 .327 3/3 3/4 0/4 4/4
Iatrogenic (GH) I1263 VV T3 0/4 .350 1/2 ND ND 1/4
vCJD I336 MM T4 0/7` .387 3/4 5/7 2/7 5/7
IPD= inherited prion disease; IHC= immunohistochemistry; IB = immunoblotting; ND= not determined; GH=growth hormone.
*According to classification of Hill et al. [53].
{Positive either by clinical signs, western blotting and/or immunohistochemistry; primary antibody was either 3F4 or ICSM 35.
`Post-inoculation survival period (days): 388, 650, 627, 694,727, 799 and 811.
doi:10.1371/journal.ppat.1003643.t002
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with vCJD transmission to the wild-type human PrP 129VV
genotype [37,40], the abundance of non-florid plaques associated
with vCJD transmission to 117V mice is remarkable and clearly
suggests a modifying effect of the mutation.
Transmission of vCJD prions to transgenic mice homozygous
for human PrP valine-129 invariably results in a strain shift from
the characteristic type 4 PrPSc molecular signature to type 5 PrPSc
[37,40]. The presence of type 5 PrPSc fragment size in vCJD-
inoculated 117VV Tg30 mouse brain (Figure 4A lane 4) compared
to type 4 PrPSc propagated in the vCJD-inoculated 129MM Tg45
control brain (lane 1) clearly shows that the 117V mutation on the
valine-129 allele does not influence the previously established
strain shift phenomenon. Interestingly, a truncated PrP peptide of
about 8 kDa that is associated with GSS A117V mutation was also
seen on longer exposure in PK-digested (Figure 4A lanes 3 and 4)
and PK-titrated samples (Figure 4B lanes 1 to 4). Notably, the
8 kDa fragment was not seen without PK digestion (lane 5
Figure 4A and 4B respectively), thus confirming this PrP fragment
as disease specific. Indeed, in some vCJD-challenged 117V Tg30
mouse brains that were positive by immunohistochemistry, only
the GSS-associated 8 kDa PrP fragment was detectable (Table 2).
Discussion
We have demonstrated that GSS A117V is indeed a transmis-
sible condition and properly designated an inherited prion disease
rather than simply a prion proteinopathy without generation of
prions. Additionally, we report that classical PrPSc is detectable in
PrP 117V transgenic mouse brain using suitable conditions. The
inability to detect classical PrPSc in patient brain had led to the
proposal that the A117V mutation may cause pathology
principally via an alternative pathway, namely through an increase
in C-terminal transmembrane PrP, designated CtmPrP, to the total
exclusion of PrPSc [8]. It has also not been shown whether or not
117V-PrPC is convertible to PrPSc. Using appropriate transgenic
models challenged with classical CJD prion isolates, we have
demonstrated that, despite the observed transmission barrier to
clinical disease which can be explained by the 117V mutation
producing a partial transmission barrier, 117V PrPC is a
competent substrate for conversion to PrPSc. Notably, the newly
generated PrPSc assumes the stable strain properties of the
exogenous PrPSc and is therefore readily detectable on immuno-
blots.
Similarly, although transmission properties of GSS A117V
prions in these mice were not typical of prion transmission to
transgenic mice expressing the homotypic substrate, our detection
of classical PrPSc is unprecedented and confirms that experimental
conditions in our 117VV transgenic mice were favourable for
replication of PrPSc. However, in contrast to the stable PrPSc
propagated from classical CJD prion transmission to these mice,
the observation that PrPSc generated from GSS A117V prions in
vivo was inherently unstable may in part explain the low clinical
attack rates observed in the present study and the failure of
previous transmission attempts. It is reasonable to infer that
because the A117V-derived abnormal PrP is labile, prion
replication and the probability of a sustained prion infection in
these mice would have been greatly enhanced by the 2–3 fold
over-expression of the substrate, 117V PrPC.
Given that the only protease-resistant PrP fragment found to-
date in A117V patients’ brains is the characteristic 8 kDa PrP
fragment [26], our 117VV Tg30 line in which only 8 kDa PrP
fragment was detectable has recapitulated the GSS A117V disease
phenotype. Since the 8 kDa peptide was only seen as a proteinase-
K resistant truncated fragment, it represents a GSS-specific PrP
Figure 4. Immunoblot analysis of abnormal PrP propagated in the brains of 117VV Tg30 transgenic mice challenged with vCJD
prions. All mice were inoculated with the same vCJD prion isolate. Immunoblots were analysed by enhanced chemiluminescence with monoclonal
anti-PrP antibody ICSM 35. The provenance of the brain samples is designated above the lanes. (A) Lanes 3 and 4 show the predicted type 5 PrPSc
bands seen when vCJD is propagated in transgenic mice expressing HuPrP with the codon 129VV genotype, compared with the detection of type 4
PrPSc in the brain of vCJD-inoculated 129MM Tg45 mouse (lanes 1 and 2). Type 5 shares the glycoform ratio of type 4 but differs in migrating more
slowly on western blots because all 3 glycoform fragments of type 5 have higher apparent molecular masses than those of type 4. The lower signal
intensity in lane 3 (100 mg/ml PK) compared to lane 4 (50 mg/ml PK) reflects PK-sensitivity of the vCJD-seeded 117V PrPSc. The 8 kDa PrP fragments
can be seen associated with only PK-digested prion-infected 117V PrP-expressing mouse brain samples. These truncated 8 kDa fragments are absent
from either vCJD infected Tg45 mice (lanes 1 and 2) or vCJD-infected 117VV Tg30 brain samples not digested with PK (lane 5).These data confirm that
the 8 kDa human PrP fragment is a disease-associated PrP degradation product. (B) Variable PK resistance in brain of 117VV Tg30 mouse inoculated
with vCJD. The 8 kDa PrP fragment is only seen in PK digested lanes 1–4, but is absent in the same sample undigested with PK (lane 5).
doi:10.1371/journal.ppat.1003643.g004
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degradation product, the detection of which can be taken as a
reliable surrogate marker for confirming prion disease in GSS
A117V patients [26]. The possibility of classical PrPSc being
present at low and undetectable levels in GSS A117V patient
brain homogenates cannot be ruled out. It therefore remains to be
determined whether the parent PrP conformer that generates the
8 kDa protease resistant PrP, is capable of initiating and sustaining
prion infection or that transmissibility remains associated with
classical PrPSc present below the threshold of detection. In this
regard, even a successful serial passage of GSS A117V-challenged
Tg30 mouse brains apparently propagating only the 8 kDa
fragment and resulting in the propagation of classical PrPSc,
may not resolve this issue.
All previous reports of PrP point mutations causing spontaneous
neurodegeneration have involved superimposing human PrP
pathogenic mutations onto rodent PrP [7,45,46], and these studies
have invariably reported very high incidences of spontaneous
neurological dysfunction. Since destabilising effects measured in a
mouse protein cannot be assumed to be equivalent in the human
protein [47,48], we have modelled the A117V mutation directly on
human PrP. This difference in approach can explain the contrasting
low incidence of spontaneous disease in our 117VV transgenic mice.
The development of neurological dysfunction in transgenic mice
expressing disease-associated mutations modelled on rodent PrP has
been described as disease acceleration [49], because PrPSc has not
been detectable and transmissibility has not been demonstrated
conclusively. In this regard, transmissibility of spontaneous PrP
plaque deposits in aged 117VV Tg30 mice is being investigated and
will be reported in a subsequent publication.
The observation that vCJD prions transmit more readily, albeit
subclinically, to 117VV Tg30 but not to 117VV Tg31 mice that
have higher PrP expression levels was unexpected. However,
whereas all vCJD-inoculated 117VV Tg31 mice had a maximum
post-inoculation survival period of 547 days (culled in the range
292–547 days), 6/7 117VV Tg30 mice challenged with the same
inoculum survived in the range of 627–811 days post-inoculation.
These data suggest that very prolonged replication periods may be
required for pathological PrP to become detectable in vCJD-
challenged 117V transgenic mice by either IHC or immunoblot-
ting. Subpassage of apparently negative brains could be used to
explore this, however this is not a central part of this study.
Our results may have wider implications for other inherited
prion diseases that have not been shown to be transmissible as yet.
Firstly, it is possible that demonstration of transmissibility of such
inherited prion diseases would require specific transgenic models
with over-expression of the relevant mutant human PrP, rather
than endogenous levels of mutant PrP expression, if transmissibil-
ity is to be demonstrated within the lifespan of a mouse. The
transient detection of PrPSc in our study suggests that A117V-
associated PrPSc is labile and readily susceptible to proteases. This
results in progressive reduction of PrPSc to undetectable, yet still
potentially infectious levels. In this regard, failure to detect low
levels of PrPSc in the past from patient brain samples could be due
to technical limitations of currently available biochemical tech-
niques, rather than its absence.
Methods
Ethics statement
Storage and biochemical analysis of human tissue samples and
transmission studies to mice were performed with written informed
consent from patients or relatives under approval from the Local
Research Ethics Committee of UCL Institute of Neurology/
National Hospital for Neurology and Neurosurgery and the code
of practice specified in the Human Tissue Authority licence held
by UCL Institute of Neurology. Work with mice was performed
under licence granted by the UK Home Office (Animals (Scientific
Procedures) Act 1986 ; Project Licence number 70/6454) and
conformed to University College London institutional and
ARRIVE guidelines.
Generation of transgenic mice
The 759 bp human PrP ORF was amplified by PCR with pfu
polymerase from genomic DNA prepared from the brain of a
patient with the inherited prion disease A117V mutation, using
forward primer 59-GTCGACCAGTCATTATGGCGAACCTT-
39 and reverse primer 59-CTCGAGAAGACCTTCCTCATCC-
CACT-39. Restriction sites Sal I and XhoI (underlined) were
introduced in the forward and reverse primers respectively for
cloning. The sequence was confirmed and ligated into the cosmid
vector CosSHaTet [33]. Microinjection of the purified DNA was
carried out according to standard protocol into single cell eggs of
Prnp null mice [38] which had been backcrossed onto an FVB/N
background. Genotyping was performed by PCR and PrP
expression levels estimated by Western blot analysis as previously
reported [50]. Two homozygous lines were established for HuPrP
117V described as Tg(HuPrP117V,129V+/+ Prnpo/o)-30 (designated
human PrP 117VV Tg30) and Tg(HuPrP117V,129V+/+ Prnpo/o)-31
(human PrP 117VV Tg31) with mutant transgene expression levels
of 2 and 3 times respectively, compared to pooled normal human
brain levels.
Transmission studies
Strict bio-safety protocols were followed. Inocula were pre-
pared, using disposable equipment for each inoculum, in a
microbiological containment level 3 laboratory and inoculations
performed within a class 1 microbiological safety cabinet. Ten
mice per group of 117VV Tg31 transgenic mice were inoculated
with prion isolates comprising human brain homogenates from:
three separate IPD A117V cases; two sporadic CJD cases; three
iatrogenic CJD cases; one case of vCJD and one mouse brain
isolate from vCJD passaged once in Tg152 mice expressing wild-
type human PrP V129 (containing type 5 PrPSc) [37,40], as
detailed in Table 1. Similarly, the second 117VV transgenic line,
117VV Tg30 mice were challenged with the same three IPD
A117V inocula, and 1 inoculum each of iatrogenic CJD and vCJD
as detailed in Table 2. All cases were neuropathologically
confirmed.
The genotype of each mouse was confirmed by PCR of tail
DNA prior to inclusion and all mice were uniquely identified by
sub-cutaneous transponders. Disposable cages were used and all
cage lids and water bottles were also uniquely identified by
transponder and remained with each cage of mice throughout the
incubation period. Mice were anaesthetised with a mixture of
halothane and O2, and intracerebrally inoculated into the right
parietal lobe with 30 ml of a 1% brain homogenate prepared in
phosphate-buffered saline (PBS). All mice were thereafter exam-
ined daily for clinical signs of prion disease. Mice were killed if
they exhibited any signs of distress or once a diagnosis of prion
disease was established.
Neuropathology and immunohistochemistry
Mice were culled by CO2 asphyxiation. Brain was fixed in 10%
buffered formol saline and then immersed in 98% formic acid for
1 hour and paraffin wax embedded. Serial sections of 4 mm
thickness were pre-treated by boiling for 10 min in a low ionic
strength buffer (2.1 mM Tris, 1.3 mM EDTA, 1.1 mM sodium
citrate, pH 7.8) before exposure to 98% formic acid for 5 min.
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Abnormal PrP accumulation was examined using anti-PrP
monoclonal antibody ICSM 35 (D-Gen Ltd, London) on a
Ventana automated immunohistochemical staining machine
(Ventana Medical Systems Inc., Tucson, Arizona) using proprie-
tary secondary detection reagents (Ventana Medical Systems Inc)
before development with 393 diaminobenzedine tetrachloride as
the chromogen. Harris haematoxylin and eosin staining was done
by conventional methods. Appropriate controls were used
throughout.
Western blotting
Preparation of brain homogenates (10% w/v in phosphate
buffered saline), proteinase K digestion (titration up to 100 mg/ml
for 1 h at 37uC), and subsequent western blotting was performed
as described previously [51]. For primary screening of both
transgenic and wild type mouse brain homogenates, blots were
probed with either a monoclonal antibody which detects human,
but not mouse, PrP (3F4 ([52])) or a biotinylated anti-PrP
monoclonal antibody which recognises both human and mouse
PrP (biotinylated-ICSM 35 (D-Gen Limited, London)) in con-
junction with an avidin-biotin-alkaline phosphatase conjugate
(Dako) and development in chemiluminescent substrate (CDP-
Star; Tropix Inc). Primary screening of brain homogenates was
performed blind to sample identity.
Supporting Information
Figure S1 H&E staining showing semi-quantitative
scale used in scoring variable neuronal loss in the
hippocampus of A117V-inoculated mice and PrP plaques
in brain of a PBS-inoculated 117VV Tg31 mouse. (A)
Coronal section of the anterior commissure on level Bregma +2 mm
showing PrP deposits in a PBS-inoculated Tg31 mouse. a, location
of PrP deposits within and surrounding the anterior commissure
(ac). Other structures seen on this level are the piriform cortex (Pir),
the anterior olfactory nucleus, medial part (AOM) and the forceps
minor of the corpus callosum (fmi). b, high power magnification of
the anterior commissure shows multiple small plaques within the
white matter and immediately adjacent to it. Note the spongiform
changes in the anterior commissure. Scale bar = 1200 mm (A) and
250 mm (B). (B) Upper row (a, c, e, g) shows progressive thinning of
the neuronal layer of the hippocampus. Lower row (b, d, f, h) shows
close up of the neuronal layer in each corresponding figure above,
with blue arrows highlighting drop outs of neurones. Definition of
values for neuronal loss: 0: No neuronal loss; +: Drop out of single
neurones either focally or within the Ammon’s horn (AH), leaving
the AH continuity intact; ++: Focal or regional drop out,
interrupting the continuity of the AH and creating a small-medium
gap (up to 1/3 of the length of the AH); +++: Neuronal drop out
leaving gaps of more than 1/3 of the AH’s length. Scale
bar= 500 mm for top panel and 125 mm for the bottom panel.
(TIF)
Figure S2 Immunoblot analyses of the brains of 117VV
Tg31 mice challenged with GSS A117V prions showing
time-course of degradation due to freeze-thawing. (A)
Samples initially digested at 100 mg/ml PK at 37uC for 1 hour
(lanes 3–8) showed variable digestion but the 8 kDa fragment was
already visible (lanes 3 and 4). (B) Repeat immunoblotting
performed on the same samples after 1 freeze-thaw, using the same
PK digestion conditions, confirmed the 8 kDa fragment as the main
detectable PrP fragment in brains of A117V-challenged Tg31 mice
(lanes 3 and 4). All other fragments are almost completely degraded
(lanes 3–8). The positive control used in lanes 1 and 2 of both panels
A and B was from a transgenic mouse expressing wild type HuPrP-
129MV challenged with sporadic CJD inoculum.
(TIF)
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